Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Blend Therapeutics secures Mark Iwicki's talents

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Layoffs at Medicis top 300, with 117 staffers chosen to stay

The layoff toll at Medicis Pharmaceutical has topped 300, the  Phoenix Business Journal  reports.

Pfizer targets 600 primary-care sales jobs

It's the end of the year, and the end of the road for hundreds of Pfizer drug reps. The company is slashing its primary-care sales force by almost 20%, Bloomberg reports, taking its 3,000-strong army of reps down to around 2,400.

Valeant cuts 200 Medicis jobs as $2.6B deal closes

Valeant Pharmaceuticals ($VRX) isn't pussyfooting around Medicis. As the built-by-acquisition Canadian company wrapped up its deal for Medicis last week, some 200 employees were told to pack their bags.

Ex-Genzyme CEO to serve as Prosensa's strategic adviser

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Endo revises earnings picture, says CEO to retire

Endo Health Solutions ($ENDP) downgraded its earnings prospects for this year and next at the same time that it announced its CEO will retire by May.

Ex-Genzyme CEO Termeer returns to his roots at biotech Prosensa

The former Genzyme CEO and chairman has joined the biotech Prosensa as a strategic adviser, bringing his experience in building Genzyme into a world leader in rare diseases.

BioCryst Pharma chops half of staff to cap tumultuous two months

BioCryst Pharmaceuticals ($BCRX) blamed recent setbacks for the company's decision to ax 50% of its workers, according to a release this morning. Its restructuring plans come a week after BioCryst and Presidio Pharmaceuticals jettisoned a $101 million merger agreement that would have brought BioCryst new assets in the sizzling hepatitis C field.

ImmunoCellular taps Andrew Gengos to serve as president

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

AZ blames German pricing for 400 job cuts

AstraZeneca ($AZN) is joining the line-up of drugmakers cutting jobs in Germany. Like the others, AstraZeneca cites the usual economic reasons, but adds a political twist. Also to blame for up to 625 job cuts? "[M]assive state intervention in the pricing of innovative medicines," the company says.